TY - CHAP M1 - Book, Section TI - Clinical Pharmacogenomics A1 - Gammal, Roseann S. A1 - Cavallari, Larisa H. A1 - Lam, Y. W. Francis A2 - DiPiro, Joseph T. A2 - Yee, Gary C. A2 - Haines, Stuart T. A2 - Nolin, Thomas D. A2 - Ellingrod, Vicki L. A2 - Posey, L. Michael Y1 - 2023 N1 - T2 - DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 12th Edition AB - KEY CONCEPTS Genetic variation contributes to pharmacokinetic and pharmacodynamic properties of medications. Genetic variation affects drug-metabolizing enzymes, transporters, and target proteins, as well as immune-related proteins that may impact medication response. Genetic polymorphisms may influence medication effectiveness and risk for toxicity. Pharmacogenomics is the study of the impact of genetic polymorphisms on medication response. The goals of pharmacogenomics are to optimize medication efficacy and limit toxicity based on an individual’s DNA. Single nucleotide polymorphisms are the most common gene variations associated with medication response. Evidence-based resources, such as US Food and Drug Administration medication labels, Clinical Pharmacogenetics Implementation Consortium Guidelines, and the Pharmacogenomics Knowledgebase, are available to help clinicians select and dose medications based on a patient’s genetic profile. The pharmacist plays a key role in advancing pharmacogenomics in clinical practice as part of a multidisciplinary healthcare team. SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1197540451 ER -